Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market
Profiles 16 China-made blockbuster drugs exceeding ¥1B sales, highlighting intense PD-1 competition, EGFR tech innovation, and bispecific antibody/non-oncology surge.
September 5, 2025
by Lezhi
Development Progress of Bispecific Antibodies in China
Approved Bispecific Antibody Products Worldwide, New progress in the field of bispecific antibodies.
November 7, 2023
by Yefenghong/PharmaSources
The Accepted Marketing Application of Roche's Glofitamab in China
Recently, the marketing application of Roche's Glofitamab has been accepted by NMPA in China.
March 1, 2023
by Yefenghong/PharmaSources
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052
Alphamab Oncology (stock code: 9966.HK) announced, that the company received the IND approval from the National Medical Products Administration (NMPA) for the company's innovative bispecific antibody KN052...
February 14, 2022
by prnasia
ImmuneOncia, WuXi Biologics partner for bispecific antibody development
ImmuneOncia Therapeutics has signed a Memorandum of Understanding (MoU) with WuXi Biologics to develop and manufacture bispecific antibody, IOH-001.
December 30, 2021
by Pharmaceutical-Technology
I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE)..
December 17, 2021
by prnasia
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody)
Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab...
December 7, 2021
by prnasia
Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of a clinical trial for HLX301, a Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients with locally advanced...
November 26, 2021
by prnasia
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026...
October 21, 2021
by prnasia
Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046
Alphamab Oncology (stock code: 9966.HK), announced that the first phase III pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-01) has successfully completed enrollment of all patients.
October 18, 2021
by prnasia
Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer...
October 13, 2021
by prnasia
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021.
September 28, 2021
by prnasia